- Policy
- MFDS promotes RWD analysis of COVID-19 vaccines & txs
- by Lee, Hye-Kyung May 18, 2022 05:51am
- The MFDS (Director Kim Kang-rip) will push for a benefit and risk assessment study from May this year based on data actually used in medical sites after the COVID-19 vaccine and PO treatment were introduced in Korea. This study was prepared to analyze safety information such as the incidence of side effects, vaccine defense effects, and hospi
- Company
- Shionogi applies to trademark its COVID-19 treatment
- by Kim, Jin-Gu May 17, 2022 06:02am
- With the domestic trademark application for the COVID-19 treatment that is being jointly developed by Shionogi Pharma and Ildong Pharmaceutical nearing completion, Shionogi Pharma and Ildong Pharmaceutical are speeding up preparations to commercialize its drug in Korea in the second half of this year. According to the Korean Intellectual
- Company
- Pharmaceutical exports fall 19% this year
- by Kim, Jin-Gu May 17, 2022 06:02am
- Pharmaceutical exports from January to April last year were found to have fallen 19% from the same period in the previous year. According to the Korea Customs Service on the 16th, pharmaceutical exports from January to April this year have recorded $2,191,880,000 (approx. &8361;2.81 trillion). This is a 19% decrease from the $2,689,820,000 (
- Company
- Why MSD raised the price of Gardasil 9 for two years?
- by May 17, 2022 06:02am
- As MSD Korea raised the supply price of Gardasil 9, a cervical cancer vaccine, by 25% in two years, attention is being paid to the background. Some interpret the decision ahead of the application of Gadasil 9's health insurance benefits, which was President Yoon Seok-yeol's pledge, or an alternative to fill the sales gap due to the reduction
- Company
- Prescription of CGRP migraine drugs to begin in earnest?
- by Eo, Yun-Ho May 17, 2022 06:01am
- CGRP-targeted migraine treatments are gaining better access as prescriptions. The first drug introduced is nearing insurance benefit listing and the second drug is landing in general hospitals. According to industry sources, the Calcitonin gene-related peptide (CGRP)-targeted migraine treatment ‘Emgality (galcanezumab)’ has passed delib
- Policy
- Discussions on the benefits of migraine txs begin in earnest
- by Lee, Tak-Sun May 16, 2022 06:14am
- As Lilly Korea's Emgality passed the HIRA's Drug Reimbursment Evaluation Committee, discussions on the benefit of the migraine txs are rapidly progressing. Following Emgality, Handok Teva's Ajovy, the same (CGRP) target treatment, is also seeking to enter the benefit. Reyvow of Ildong Pharmaceutical, which was approved in Korea on the 12th
- Company
- Servier launches supply of new acute leukemia drug Oncaspar
- by Eo, Yun-Ho May 16, 2022 06:14am
- Servier Korea began supplying Oncaspar Lyophilized Inj, a combination treatment for "acute lymphocytic leukemia (ALL)" from the 10th. It was supplied through the rare drug center, but the license holder, Servier, was in charge of the supply, and insurance benefits have not yet been registered. Servier Korea is undergoing prescription procedur
- Company
- Huons' local anesthetics export contract with FPI Canada
- by Kim, Jin-Gu May 16, 2022 06:14am
- Huons announced on the 13th that it has signed an export contract with Canadian pharmaceutical company Formative Pharma Inc (FPI). Items signed an export contract are▲1% Lidocaine hydrochloride injection 5mL, ▲ 0.75% Bupivacaine hydrochloride injection 2ml, and ▲ 1% lidocaine hydrochloride injection 5mL vial. These items were obtained from
- Policy
- Daewoong’s P-CAB drug Fexclu receives conditional approval
- by Lee, Tak-Sun May 16, 2022 06:14am
- Daewoong Pharmaceutical’s P-CAB class gastroesophageal reflux disease (GERD) treatment ‘Fexclu’ has received conditional approval from the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee. The committee decided reimbursement was appropriate for the drugs if the company accepts a price below the apprais
- Company
- The introduction of Biogen Aduhelm in Korea is also unclear
- by May 16, 2022 06:13am
- Biogen has decided to minimize the commercialization infrastructure of the Alzheimer's drug Aduhelm and focus on developing subsequent drugs. In fact, it is unclear whether Aduhelm, which is in the process of eviction, will be introduced in Korea. Biogen announced in its first-quarter earnings announcement on the 3rd (local time) that CEO
